Single-use Bioreactors Market - By Product (Stirred Tank, Wave-mixed, Bubble Column), Cell (Mammalian, Bacterial, Yeast), Molecule (Monoclonal Antibodies, Vaccines, Recombinant Proteins), Usage, End-use- Global Forecast, 2023-2032

Description

List of Tables

Global Single-use Bioreactors Market will register a 15.5% CAGR from 2023 to 2032, propelled by the remarkable advancements in healthcare and the inherent flexibility of single-use bioprocessing technologies. The increasing demand for biopharmaceuticals, driven by a surge in precision medicine and therapeutic innovations, underscores the significance of these advancements. Single-use bioreactors, owing to their adaptable and cost-effective nature, emerge as pivotal tools in meeting the evolving needs of the healthcare sector, thereby significantly contributing to the industry landscape.

For instance, in 2023, Getinge launched the AppliFlex ST GMP, an innovative single-use bioreactor system crafted to smoothly connect the realms of research and clinical production in cell and gene therapy, along with mRNA production. This launch bolsters the market share by seamlessly integrating cutting-edge healthcare advancements and the intrinsic flexibility of single-use bioprocessing technologies.

The single-use bioreactors market is segregated based on molecule, cell, and region.

The monoclonal antibodies (mAbs) segment will garner substantial gains through 2032. This prominence stems from the increasing therapeutic applications of mAbs, particularly in treating cancer and autoimmune diseases. Their high specificity, therapeutic efficacy, and rising demand for personalized medicine contribute to their prominence in bioprocessing. As the pharmaceutical landscape prioritizes precision and targeted therapies, the role of monoclonal antibodies within single-use bioreactors becomes pivotal, shaping the bioreactors market outlook.

The bacterial cell segment will capture a remarkable revenue share by 2032 due to the widespread application of bacterial cells in various bioprocessing activities, including the production of vaccines, enzymes, and biotherapeutics. The versatility, scalability, and cost-effectiveness of utilizing bacterial cells contribute to their prominence. As the demand for biopharmaceuticals continues to escalate, the prevalence of bacterial cell-based processes will position them as a pivotal driver in carving a healthy market growth trajectory.

APAC single-use bioreactors market size will expand at a notable CAGR from 2023 to 2032, fueled by a confluence of factors, including the growing demand for biopharmaceuticals, increasing investments in research and development, and a burgeoning biotechnology sector. Favorable regulatory environments, in line with the region's robust manufacturing capabilities, contribute to its prominence. As the global pharmaceutical landscape continues to evolve, the Asia-Pacific market stands as a key contributor, driving innovation and shaping the future of single-use bioreactors.

Product Code: 6940

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Base estimates & workings
1.3 Forecast calculations
1.4 Data Sources
- 1.4.1 Primary
- 1.4.2 Secondary
  - 1.4.2.1 Paid sources
  - 1.4.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Global single-use bioreactors market 360 degree synopsis, 2018 - 2032
2.2 Regional trends
2.3 Product trends
2.4 Cell trends
2.5 Molecule trends
2.6 Usage trends
2.7 End-use trends

Chapter 3 Single-use Bioreactors Industry Insights

3.1 COVID- 19 impact analysis
3.2 Industry ecosystem analysis
3.3 Technology landscape
3.4 Regulatory landscape
3.5 Industry impact forces
- 3.5.1 Growth drivers
  - 3.5.1.1 Growing pharmaceutical and biotechnology industry
  - 3.5.1.2 Technological advancements in single-use bioreactors
  - 3.5.1.3 Growing focus on orphan drug development
  - 3.5.1.4 Rising demand for personalized medicines
- 3.5.2 Industry pitfalls & challenges
  - 3.5.2.1 Low capacity of single-use bioreactors
  - 3.5.2.2 Concerns regarding extractables and/or leachables
3.6 Growth potential analysis
- 3.6.1 By product
- 3.6.2 By cell
- 3.6.3 By molecule
- 3.6.4 By usage
- 3.6.5 By end-use
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
- 4.1.1 Thermo Fisher Scientific Inc.
- 4.1.2 Danaher Corporation
- 4.1.3 Merck KGaA
4.2 Competitive analysis of major market players, 2022
4.3 Competitive positioning matrix, 2022
4.4 Strategic outlook matrix, 2022

Chapter 5 Single-use Bioreactors Market Size and Forecast, By Product, 2018-2032 (USD Million)

5.1 Key trends, by product
5.2 Stirred tank single-use bioreactors
5.3 Wave-mixed single-use bioreactors
5.4 Bubble column single-use bioreactors
5.5 Other products

Chapter 6 Single-use Bioreactors Market Size and Forecast, By Cell , 2018-2032 (USD Million)

6.1 Key trends, by cell
6.2 Mammalian cells
6.3 Bacterial cells
6.4 Yeast cells
6.5 Other cells

Chapter 7 Single-use Bioreactors Market Size and Forecast, By Molecule, 2018-2032 (USD Million)

7.1 Key trends, by molecule
7.2 Monoclonal antibodies
7.3 Vaccines
7.4 Recombinant proteins
7.5 Stem cells
7.6 Gene therapy
7.7 Other molecules

Chapter 8 Single-use Bioreactors Market Size and Forecast, By Usage, 2018-2032 (USD Million)

8.1 Key trends, by usage
8.2 Developmental, pre-clinical & clinical
8.3 Commercial production

Chapter 9 Single-use Bioreactors Market Size and Forecast, By End-use, 2018-2032 (USD Million)

9.1 Key trends, by end-use
9.2 R&D organizations
9.3 Biopharma manufacturers
9.4 Contract manufacturing organizations

Chapter 10 Single-use Bioreactors Market Size and Forecast, By Region, 2018-2032 (USD Million)

10.1 Key trends, by region
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Italy
- 10.3.5 Spain
- 10.3.6 The Netherlands
- 10.3.7 Denmark
- 10.3.8 Rest of Europe
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Singapore
- 10.4.7 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East & Africa
- 10.6.1 South Africa
- 10.6.2 UAE
- 10.6.3 Rest of Middle East & Africa

Chapter 11 Company Profiles

11.1 Thermo Fisher Scientific
11.2 Solaris Biotech Solutions
11.3 Shanghai Bailun Biotechnology Co. Ltd.
11.4 Sartorius Stedim Biotech Group
11.5 Pierre Guerin Sas (Engie)
11.6 PBS Biotech
11.7 Danaher Corporation
11.8 Merck Group
11.9 GEA Group Aktiengesellschaft
11.10 Eppendorf AG
11.11 CESCO Bioengineering Co. Ltd.
11.12 CerCell ApS
11.13 Cellexus Ltd
11.14 Bbi Biotech
11.15 Applikon Biotechnology, Inc. (Getinge)